Market Overview

Lipocine Pops And Drops After LPCN 1021 Meets Primary Endpoint


Lipocine Inc (NASDAQ: LPCN) shares are trading higher by 22 cents (4.4 percent) at $4.24 in Tuesday's session.

After Monday's close, the company announced that LPCN 1021 had met its primary endpoint. The drug "is a novel oral product candidate of Testosterone (T) containing Testosterone Undecanoate (TU) that is designed to help restore normal T levels in males for conditions associated with a deficiency or absence of endogenous testosterone."

After a much higher open, Lipocine immediately peaked at $5.14 and reversed course as profit-takes swarmed the stock. That marks the first time it has been over $5.00 since October 12, 2016, when it peaked at $5.42, but weakened to end that session at $4.60.

At this time, the retreat is attempting to find support near the top of Monday's range ($4.12) as $4.16 stands as the current low for the session.

Posted-In: Technicals Intraday Update Movers Trading Ideas


Related Articles (LPCN)

View Comments and Join the Discussion!
Lightning Fast
Market News Service
$199 Free 14 Day Trial
Book A Demo
Learn How You Can Succeed In The Market With Benzinga Pro

Fastest Market News

Real-Time News Alerts

Customizable News Filters

Book A Demo

More Cash Cow ETFs Mooove To Market

Lennar's Wild Ride After Q2 Beat